The next Uppsala Monitoring Centre research conference will be making the case for evidence of impact.
UMC has been closely monitoring the COVID-19 (Coronavirus) outbreak and after careful consideration has decided to postpone the scheduled Uppsala Forum until next year in view of the current situation and the efforts of public health authorities in affected countries to control and prevent the disease from spreading further. The dates for the next forum are now 11-12 May 2021.
In 2018, Uppsala Forum was replaced by UMC’s 40th Anniversary conference, where key actors from the past and present of the WHO Programme for International Drug Monitoring joined pharmacovigilance colleagues to reflect on the progress pharmacovigilance has made since the programme’s inception in 1968.
The need to develop and rapidly deploy new treatments tests the limits of traditional pharmacovigilance and demands new thinking and practice. How can we ensure the safety of patients using new drugs when rapid access is of paramount importance?
Topics covered included: Patient groups at risk – genotypes and phenotypes; Structure analysis of medicinal products; Detection and confirmation of signals; Individualised benefit-risk assessment; Effective communication to health professionals and patients in clinical settings.
Causality assessment plays a critical part in the search for better science and safer use of medicines. Although the principles of causality assessment are straightforward, the application of those principles to an individual case is a philosophical as well as a scientific challenge.